Diversified healthcare company CVS Health (NYSE:CVS) reported Q4 CY2025 results exceeding the market’s revenue expectations, ...

CVS Health reported higher fourth-quarter and full-year revenues in 2025, driven by growth across its pharmacy, health ...

CVS Health reported $2.9 billion in fourth quarter net income as the company begins to get a handle on costs that have hit ...

CVS Health Corp (NYSE:CVS) on Tuesday reported stronger-than-expected fourth-quarter revenue and adjusted earnings, driven by growth across its pharmacy, health services, and insurance businesses. The ...

CVS Health Corporation (NYSE:CVS) is included among 12 Unstoppable Dividend Stocks to Buy According to Analysts. On January ...

CVS Health reported less than $1.8 billion profit in 2025, down 61.8% year over year, according to a Feb. 10 earnings release. Fourth-quarter net income attributable to CVS Health was $2.9 billion, up ...

CVS Health this morning reported earnings in line with expectations. In 2025, the giant healthcare company saw record earnings of $402.1 billion, up 7.8% compared with the year before. The lull-year ...

CVS Health Corp. CVS on Tuesday reported fourth-quarter fiscal 2025 results. The company reported sales of $105.69 billion, ...

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...

(Corrects paragraph 5 in February 5 story to say 2025 Prolia sales were $4.4 billion, not $1.05 billion) Feb 5 (Reuters) - ...